Publications by authors named "Michael Bargfrede"

Claim this Profile
P
Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Xiaofei Zhou, A Craig Lockhart, Siqing Fu, John Nemunaitis, John Sarantopoulos, Michael Bargfrede

J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Xiaofei Zhou, Shubham Pant, John Nemunaitis, A Craig Lockhart, Gerald Falchook, Michael Bargfrede

Invest New Drugs· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede

Clin Pharmacokinet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Daniel P Petrylak, Jitendra G Gandhi, William R Clark, Elisabeth Heath, Jianqing Lin, Michael Bargfrede

Invest New Drugs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.
Karthik Venkatakrishnan, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede

Br J Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.
Karthik Venkatakrishnan, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede

Br J Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis